Edition:
United States

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

14.00USD
26 Sep 2016
Change (% chg)

$-0.31 (-2.17%)
Prev Close
$14.31
Open
$14.32
Day's High
$14.42
Day's Low
$13.09
Volume
84,384
Avg. Vol
221,170
52-wk High
$15.83
52-wk Low
$3.45

NERV.OQ

Chart for NERV.OQ

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio include MIN-101 for the treatment of schizophrenia... (more)

Overall

Beta: --
Market Cap(Mil.): $498.06
Shares Outstanding(Mil.): 34.81
Dividend: --
Yield (%): --

Financials

  NERV.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -1.05 -- --
ROI: -23.92 -0.26 13.91
ROE: -29.21 -3.05 14.82

BRIEF-Minerva Neurosciences provides update on clinical programs

* Statistically significant benefit of MIN-101 was also demonstrated in multiple secondary endpoints Source text for Eikon: Further company coverage:

Sep 26 2016

BRIEF-Minerva Neurosciences reports quarterly loss per share $0.18

* Expects that its cash, cash equivalents and marketable securities on hand at June 30, 2016 will be sufficient to fund its operations into 2018 Source text for Eikon: Further company coverage:

Aug 04 2016

BRIEF-Minerva Neurosciences prices of public offering of common stock

* Minerva Neurosciences announces pricing of public offering of common stock Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 14 2016

BRIEF-Minerva Neurosciences announces proposed public offering of common stock

* Minerva Neurosciences announces proposed public offering of common stock

Jun 13 2016

BRIEF-Minerva neurosciences announces proposed public offering of common stock

* Minerva neurosciences announces proposed public offering of common stock

Jun 13 2016

BRIEF-Minerva Neurosciences announces positive results in Phase IIA trial of MIN-117

* Minerva Neurosciences announces positive results in Phase IIA trial of MIN-117 in major depressive disorder Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 26 2016

BRIEF-Minerva Neuro announces positive results from phase IIB trial of MIN-101 monotherapy in schizophrenia

* Minerva neurosciences announces positive results from phase IIB trial of min-101 monotherapy in schizophrenia

May 26 2016

BRIEF-Minerva Neurosciences reports Q1 loss per share $0.29

* Minerva Neurosciences reports first quarter 2016 financial results and business updates

May 03 2016

BRIEF-Minerva Neurosciences reports Q1 loss per share $0.29

* Minerva Neurosciences reports first quarter 2016 financial results and business updates

May 03 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.